勘误：抗OX40单克隆抗体KHK4083用于中度活动性溃疡性结肠炎的随机、剂量递增2期研究
Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.
作者信息
Kierkus Jaroslaw, Pesegova Marina, Klopocka Maria, Brankovic Marija, Kasai Noriyuki, Efuni Sergey, Kong Jennifer, Nakajima Yu, Jordan Christina, Matsui Takeshi, Feagan Brian G, Strout Vincent
出版信息
Crohns Colitis 360. 2020 Dec 17;2(4):otaa092. doi: 10.1093/crocol/otaa092. eCollection 2020 Oct.
Abstract
[This corrects the article DOI: 10.1093/crocol/otaa049.].
摘要
[本文更正了文章DOI：10.1093/crocol/otaa049。]
相似文献
1
Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.勘误：抗OX40单克隆抗体KHK4083用于中度活动性溃疡性结肠炎的随机、剂量递增2期研究
Crohns Colitis 360. 2020 Dec 17;2(4):otaa092. doi: 10.1093/crocol/otaa092. eCollection 2020 Oct.
2
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.抗OX40单克隆抗体KHK4083治疗中度活动性溃疡性结肠炎的随机、剂量递增2期研究
Crohns Colitis 360. 2020 Jun 9;2(3):otaa049. doi: 10.1093/crocol/otaa049. eCollection 2020 Jul.
3
A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis.一项关于 KHK4083 的 1 期研究：一项在健康成年人中进行的单盲、随机、安慰剂对照的单次递增剂量研究，以及一项在溃疡性结肠炎患者中进行的开放标签、多剂量研究。
Clin Pharmacol Drug Dev. 2021 Aug;10(8):870-883. doi: 10.1002/cpdd.918. Epub 2021 Jan 29.
4
Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.一项评估 KHK4083（一种抗 OX40 单克隆抗体）治疗轻至中度斑块型银屑病患者的 I 期随机研究。
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1324-1332. doi: 10.1111/jdv.14313. Epub 2017 Jun 14.
5
Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.在日本中重度特应性皮炎患者中，重复静脉输注 KHK4083（一种全人源抗 OX40 单克隆抗体）的安全性、耐受性和疗效。
J Dermatol Sci. 2020 Aug;99(2):82-89. doi: 10.1016/j.jdermsci.2020.06.005. Epub 2020 Jun 13.
6
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.依特利珠单抗与英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）的随机、双盲、双模拟、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.
7
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.依特立珠单抗诱导和维持治疗中重度溃疡性结肠炎的疗效和安全性：一项随机、双盲、安慰剂对照的 3 期临床研究
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.
8
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.随机临床试验：抗基质金属蛋白酶-9单克隆抗体GS-5745与安慰剂治疗溃疡性结肠炎的1期剂量范围研究。
Aliment Pharmacol Ther. 2016 Jul;44(2):157-69. doi: 10.1111/apt.13653. Epub 2016 May 24.
9
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.依特利珠单抗用于中重度活动性溃疡性结肠炎患者的维持治疗（LAUREL）：一项随机、安慰剂对照、双盲、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17.
10
Erratum: Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.勘误：使用马尔可夫模型评估维多珠单抗在日本溃疡性结肠炎治疗模式中的最佳位置。
Crohns Colitis 360. 2020 May 30;2(2):otaa036. doi: 10.1093/crocol/otaa036. eCollection 2020 Apr.
Zotero 插件